These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12773653)

  • 1. Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
    Tashima KT; Carpenter CC
    N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV infection--a new drug and new costs.
    Steinbrook R
    N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643
    [No Abstract]   [Full Text] [Related]  

  • 3. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 5. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 6. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 8. Enfuvirtide for prophylaxis against HIV infection.
    Cuzin L; Alvarez M
    N Engl J Med; 2003 Nov; 349(22):2169-70; author reply 2169-70. PubMed ID: 14645649
    [No Abstract]   [Full Text] [Related]  

  • 9. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 10. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 12. Enfurvirtide safety in human immunodeficiency virus-infected children.
    Baylor MS; Johann-Liang R
    Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.
    Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775
    [No Abstract]   [Full Text] [Related]  

  • 15. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 16. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
    Beilke MA
    Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

  • 19. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide approved for defusing HIV.
    Burton A
    Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.